Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Mol Pharmacol. 2012 Jun;81(6):811-9. doi: 10.1124/mol.112.077735. Epub 2012 Mar 7.
Proliferating cell nuclear antigen (PCNA), a potential anticancer target, forms a homotrimer and is required for DNA replication and numerous other cellular processes. The purpose of this study was to identify novel small molecules that modulate PCNA activity to affect tumor cell proliferation. An in silico screen of a compound library against a crystal structure of PCNA and a subsequent structural similarity search of the ZINC chemical database were carried out to derive relevant docking partners. Nine compounds, termed PCNA inhibitors (PCNA-Is), were selected for further characterization. PCNA-I1 selectively bound to PCNA trimers with a dissociation constant (K(d)) of ~0.2 to 0.4 μM. PCNA-Is promoted the formation of SDS-refractory PCNA trimers. PCNA-I1 dose- and time-dependently reduced the chromatin-associated PCNA in cells. Consistent with its effects on PCNA trimer stabilization, PCNA-I1 inhibited the growth of tumor cells of various tissue types with an IC(50) of ~0.2 μM, whereas it affected the growth of nontransformed cells at significantly higher concentrations (IC(50), ~1.6 μM). Moreover, uptake of BrdU was dose-dependently reduced in cells treated with PCNA-I1. Mechanistically the PCNA-Is mimicked the effect of PCNA knockdown by siRNA, inducing cancer cell arrest at both the S and G(2)/M phases. Thus, we have identified a class of compounds that can directly bind to PCNA, stabilize PCNA trimers, reduce PCNA association with chromatin, and inhibit tumor cell growth by inducing a cell cycle arrest. They are valuable tools in studying PCNA function and may be useful for future PCNA-targeted cancer therapy.
增殖细胞核抗原(PCNA)是一种潜在的抗癌靶点,它形成三聚体,是 DNA 复制和许多其他细胞过程所必需的。本研究的目的是鉴定能调节 PCNA 活性以影响肿瘤细胞增殖的新型小分子。对 PCNA 晶体结构进行计算机筛选和随后对 ZINC 化学数据库进行结构相似性搜索,以获得相关的对接伙伴。选择了 9 种化合物,称为 PCNA 抑制剂(PCNA-Is)进行进一步表征。PCNA-I1 选择性地与 PCNA 三聚体结合,解离常数(Kd)约为 0.2 到 0.4 μM。PCNA-Is 促进 SDS 抗性 PCNA 三聚体的形成。PCNA-I1 剂量和时间依赖性地降低细胞中染色质相关的 PCNA。与稳定 PCNA 三聚体的作用一致,PCNA-I1 以约 0.2 μM 的 IC50 抑制各种组织类型的肿瘤细胞生长,而在显著更高的浓度(IC50,约 1.6 μM)影响非转化细胞的生长。此外,用 PCNA-I1 处理的细胞中 BrdU 的摄取呈剂量依赖性降低。从机制上讲,PCNA-Is 模拟了 PCNA 敲低的效果,通过 siRNA 诱导癌细胞在 S 和 G2/M 期停滞。因此,我们已经鉴定出一类能够直接与 PCNA 结合、稳定 PCNA 三聚体、减少 PCNA 与染色质的结合并通过诱导细胞周期停滞来抑制肿瘤细胞生长的化合物。它们是研究 PCNA 功能的有价值的工具,并且可能对未来基于 PCNA 的癌症治疗有用。